Adults who have an overactive bladder and nocturia might benefit from solifenacin, which may improve quality of sleep and sleep-related quality of life by decreasing the number of overnight trips to the bathroom and increasing the amount of urination per trip. Solifenacin is a urinary antispasmodic approved by the US Food and Drug Administration (FDA) for use in adults in 2005. It works by relaxing bladder muscles to prevent urgent, frequent, or uncontrolled urination.
These new findings come from a subgroup exploratory analysis of 962 Japanese men and women, 20 years or older with overactive bladder and nocturia, who participated in a randomized, controlled 12-week trial study evaluating solifenacen (5 and 10 milligrams) against a placebo. Only participants who urinated at least once overnight were included in the analysis. The participants recorded their results in a bladder diary. While the decrease in nocturia was statistically significant for those given 10 milligrams of solifenacen, the results were not statistically significant for those given 5 milligrams.
Both the 5mg and 10mg dose significantly increased the amount of urination per trip to the bathroom by 30 and 41 milliliters, respectively. With both doses, the amount of undisturbed sleep time increased by an average of 59 and 60 minutes, respectively, compared to 33 minutes with the placebo. The study showed most significant improvements in sleep-related quality of life. Because of the exploratory nature of this study, the authors of the Journal of Urology report caution that the results need to be interpreted with caution. The analysis was supported by Astellas Pharma Inc.